Understanding the costs of drug-related actions is an important aspect of drug policy. Some of the funds allocated by governments for expenditure on tasks related to drugs are identified as such in the budget (‘labelled’). Often, however, most drug-related expenditure is not identified (‘unlabelled’) and must be estimated using modelling approaches.
The mid-term national action plan on drugs for 2011-12 included an associated budget, providing comprehensive estimates of planned, labelled and executed drug-related expenditure.
During 2011-12, planned labelled drug-related expenditure amounted to approximately 0.07 % of gross domestic product. Available comparable data on executed expenditure are limited and relate mainly to the health sector; however, these data suggest that public austerity affected the financing of drug-related services, with indications that drug-related expenditure declined markedly in Greece between 2011 and 2014.